Literature DB >> 16792508

Genetic ablation of Ptprj, a mouse cancer susceptibility gene, results in normal growth and development and does not predispose to spontaneous tumorigenesis.

Francesco Trapasso1, Alessandra Drusco, Stefan Costinean, Hansjuerg Alder, Rami I Aqeilan, Rodolfo Iuliano, Eugenio Gaudio, Cinzia Raso, Nicola Zanesi, Carlo M Croce, Alfredo Fusco.   

Abstract

Ptprj is a ubiquitously expressed murine gene encoding a receptor-type protein tyrosine phosphatase, which has recently been proposed as a candidate gene on the locus Scc1 for colon cancer susceptibility. It has been demonstrated that PTPRJ, the human homologue of Ptprj, is involved in the control of cell growth and adhesion, being furthermore altered in several types of cancer including mammary, thyroid, lung, colon, and pancreatic cancers. To investigate the biological functions of Ptprj, we have generated mice deficient in this receptor protein tyrosine phosphatase. Ptprj-deficient mice are viable, fertile, and show no gross anatomical alterations. Furthermore, neither changes in life span nor spontaneous tumor appearance were observed in Ptprj-null mice. Our results indicate that Ptprj is dispensable for normal growth and development in mice.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16792508     DOI: 10.1089/dna.2006.25.376

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  24 in total

1.  Thrombospondin-1 acts as a ligand for CD148 tyrosine phosphatase.

Authors:  Keiko Takahashi; Raymond L Mernaugh; David B Friedman; Rebecca Weller; Nobuo Tsuboi; Hironobu Yamashita; Vito Quaranta; Takamune Takahashi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-23       Impact factor: 11.205

Review 2.  Targeting protein tyrosine phosphatases for anticancer drug discovery.

Authors:  Latanya M Scott; Harshani R Lawrence; Saïd M Sebti; Nicholas J Lawrence; Jie Wu
Journal:  Curr Pharm Des       Date:  2010-06       Impact factor: 3.116

3.  Substrate specificity of R3 receptor-like protein-tyrosine phosphatase subfamily toward receptor protein-tyrosine kinases.

Authors:  Juichi Sakuraba; Takafumi Shintani; Sachiko Tani; Masaharu Noda
Journal:  J Biol Chem       Date:  2013-06-28       Impact factor: 5.157

4.  Loss of DEP-1 (Ptprj) promotes myeloproliferative disease in FLT3-ITD acute myeloid leukemia.

Authors:  Anne Kresinsky; Reinhard Bauer; Tina M Schnöder; Tobias Berg; Daria Meyer; Volker Ast; Rainer König; Hubert Serve; Florian H Heidel; Frank-D Böhmer; Jörg P Müller
Journal:  Haematologica       Date:  2018-06-07       Impact factor: 9.941

Review 5.  Modulation of VEGF receptor 2 signaling by protein phosphatases.

Authors:  Federico Corti; Michael Simons
Journal:  Pharmacol Res       Date:  2016-11-23       Impact factor: 7.658

Review 6.  Inside the human cancer tyrosine phosphatome.

Authors:  Sofi G Julien; Nadia Dubé; Serge Hardy; Michel L Tremblay
Journal:  Nat Rev Cancer       Date:  2011-01       Impact factor: 60.716

Review 7.  CD45, CD148, and Lyp/Pep: critical phosphatases regulating Src family kinase signaling networks in immune cells.

Authors:  Michelle L Hermiston; Julie Zikherman; Jing W Zhu
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

8.  Protein Tyrosine Phosphatase Receptor Type J (PTPRJ) Regulates Retinal Axonal Projections by Inhibiting Eph and Abl Kinases in Mice.

Authors:  Yang Yu; Takafumi Shintani; Yasushi Takeuchi; Takuji Shirasawa; Masaharu Noda
Journal:  J Neurosci       Date:  2018-08-06       Impact factor: 6.167

9.  VE-PTP controls blood vessel development by balancing Tie-2 activity.

Authors:  Mark Winderlich; Linda Keller; Giuseppe Cagna; Andre Broermann; Olena Kamenyeva; Friedemann Kiefer; Urban Deutsch; Astrid F Nottebaum; Dietmar Vestweber
Journal:  J Cell Biol       Date:  2009-05-18       Impact factor: 10.539

Review 10.  Protein tyrosine phosphatases in glioma biology.

Authors:  Anna C Navis; Monique van den Eijnden; Jan T G Schepens; Rob Hooft van Huijsduijnen; Pieter Wesseling; Wiljan J A J Hendriks
Journal:  Acta Neuropathol       Date:  2009-11-21       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.